Meeting
2023 ASCO Annual Meeting
Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.
Authors
Olga Kantor
Brigham and Women's Hospital, Boston, MA
Olga Kantor , Lisa A. Newman , Lauren K Anderson , Charity Glass , Erica L. Mayer , Esther R. Ogayo , Mariana Chavez-MacGregor , Rachel A. Freedman , Tari A. King , Elizabeth A. Mittendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT 02445391
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 586)
DOI
10.1200/JCO.2023.41.16_suppl.586
Abstract #
586
Poster Bd #
416
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
First Author: Frederik Marmé
First Author: Sara M. Tolaney
Poster
2023 ASCO Annual Meeting
Social determinants of health and utilization of neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC) in the community oncology setting.
First Author: Michael A. Danso
Poster
2023 ASCO Annual Meeting
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.
First Author: Marie N. Becker